Focused on solving unmet needs in ophthalmology

 

Our pipeline of topical drug candidates promises improvement in drug delivery for the back and front of the eye
 
Product candidate
Investigational indication(s)
Pre-Clinical
Phase I
Phase II
Phase III
Advanced Programs
OCS-01
DIABETIC MACULAR EDEMA
 
OCS-01
POST-CATARACT SURGERY INFLAMMATION
 
OCS-02
DRY EYE
Oculis Pre-Clinical Pipeline
OCS-03
FRONT AND BACK OF THE EYE INDICATIONS
 
OCS-04
BACK OF THE EYE INDICATION(S)
 
OCS-05
BACK OF THE EYE INDICATION(S)

OCS-01, OCS-03, OCS-04, OCS-05 are based on SNP technology while OCS-02 is based on single chain antibody fragment (scFv) against TNFα

OCS-01: A potential paradigm shift in DME treatment

Our most advanced product candidate, OCS-01, is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments and enhances their bioavailability in the relevant eye tissues. If approved in DME, it has the potential to provide a new option for patients.

OCS-01: A potential treatment for Post-cataract Surgery Inflammation

Because patients undergoing cataract surgery are usually on several medications daily, adding more eye drops can be challenging. A long-acting topical solution such as OCS-01 has the potential of reducing the frequency of the burden of administration to patients.

OCS-02: Potentially the first topical anti-TNF alpha therapy for ophthalmic indications

The compound, named OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including two controlled studies under IND. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye including Dry Eye Disease.